Karine Rossignol, Smart Immune CEO (Laurent Attias/Smart Immune)

Scoop: Smart Im­mune tar­gets $54M Se­ries A to ad­vance T cell prog­en­i­tor ther­a­py: #Jef­feries23

French biotech Smart Im­mune has raised more than half of its rough­ly €50 mil­lion ($54 mil­lion) tar­get in an on­go­ing Se­ries A round, with an eye to com­plet­ing Phase I/II de­vel­op­ment for its lead cell ther­a­py pro­gram in two dif­fer­ent in­di­ca­tions, End­points News has learned.

The Se­ries A should be com­plet­ed in ear­ly 2024, CEO Karine Rossig­nol told End­points on the side­lines of the Jef­feries health­care meet­ing Tues­day. “We need to have a mix of Eu­ro­pean in­vestors, US in­vestors and ide­al­ly phar­ma in­vestors,” Rossig­nol said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.